BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines total Research & Development Expense ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations & MD&A
Latest, FY2025
2,146
Period ended Dec 31, 2025
Change on a year earlier
+9.9%
1,953 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Research & Development Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,146 | +9.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 1,953 | +9.8% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 1,779 | +8.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 1,641 | +12.4% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 1,459 | +12.7% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 1,295 | +39.6% | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 927 | +36.6% | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 679 | +152.4% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 269 | +174.5% | Form 10-K (filed 2020-03-02) ↗ |
| FY2016 | Dec 31, 2016 | 98 | +68.4% | Form 10-K (filed 2019-02-28) ↗ |
| FY2015 | Dec 31, 2015 | 58.2 | – | Form 10-K (filed 2018-02-28) ↗ |
Breakdown
What makes up total research & development expense ($m)
Cite this data
StockData. (2026). BeOne Medicines Total Research & Development Expense ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_total
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.